Mindera Health™ announces publication of positive results from STAMP-1 and STAMP-2 studies
16 nov. 2021 11h30 HE
|
Mindera Health
San Diego, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Mindera Health™, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in psoriasis,...
Mindera Health™ announces first patient enrolled in the MATCH Study: a clinical utility evaluation of the impact of Mind.Px™ on response rates of psoriasis patients who are prescribed biologics
21 oct. 2021 12h00 HE
|
Mindera Health
San Diego, CA, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Mindera Health, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in psoriasis,...
Mindera Corporation Shifts Name to Mindera Health to Sharpen Focus on Its Personalized Medicine Platform
05 oct. 2021 11h00 HE
|
Mindera Health
San Diego, CA, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Mindera Corporation, developers of the groundbreaking Mind.Px™ - the first realization of truly personalized medicine in psoriasis - has changed its...